Skip to main content

Table 1 Virus strain composition and antigenic content of each annual influenza vaccine

From: Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial

Vaccine dosage and route*

Strain composition

Year 1:

Northern Hemisphere 2003–2004 formulation:

3 μg ID or

A/New Caledonia/20/99 (H1N1) (A/New Caledonia/20/99-like strain)

6 μg ID or

A/Panama/2007/99 (H3N2) (A/Moscow/10/99-like strain)

15 μg IM

B/Shandong/7/97 (B/Hong Kong/330/2001-like strain)

Year 2:

Northern Hemisphere 2004–2005 formulation:

9 μg ID or

A/New Caledonia/20/99 (H1N1) (A/New Caledonia/20/99-like strain)

15 μg IM

A/Wyoming/3/2003 (H3N2) (A/Fujian/411/2002-like strain)

B/Jiangsu/10/2003 (B/Shanghai/361/2002-like strain)

Year 3:

Southern Hemisphere 2005 formulation:

9 μg ID, or

A/New Caledonia/20/99 IVR-116 (H1N1) (A/New Caledonia/20/99-like strain)

15 μg IM

A/Wellington/1/2004 IVR-139 (H3N2) (A/Wellington/1/2004-like strain)

B/Jiangsu/10/2003 (B/Shanghai/361/2002-like strain)

  1. *Intradermal (ID) vaccines were formulated to contain 3, 6, 9 μg of haemagglutinin (HA) per strain in a volume of 0.1 ml and administered by microinjection; the intramuscular (IM) vaccine was the licensed vaccine Vaxigrip®, containing 15 μg of (HA) per strain in a volume of 0.5 ml.